Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy

12 novembre 2026 aggiornato da: Yonsei University

Somatic and Visceral Analgesic Efficacy and Opioid-Sparing Effect of Ultrasound-Guided Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy: A Randomized Controlled Trial

This prospective randomized controlled study will compare the postoperative analgesic efficacy and opioid-sparing effect of ultrasound-guided bilateral intertransverse process block (ITPB) with bilateral transversus abdominis plane (TAP) block combined with rectus sheath block in adults undergoing elective robotic or laparoscopic hepatectomy. A total of 64 participants will be randomly assigned in a 1:1 ratio to the ITPB group or the TAP block group. Both groups will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. The primary outcome is cumulative opioid consumption during the first 24 hours after surgery, expressed as intravenous morphine equivalents. Secondary outcomes include cumulative opioid consumption through 72 hours, incisional and visceral pain intensity, shoulder pain, sensory block distribution, rescue analgesic use, quality of recovery, postoperative recovery parameters, and adverse events.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Eligible adults scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia will be screened according to the predefined inclusion and exclusion criteria. After written informed consent is obtained, participants will receive preoperative education regarding pain assessment and patient-controlled analgesia and will complete the baseline Quality of Recovery-15 assessment.

On the day of surgery, participants will be randomly assigned in a 1:1 ratio using a computer-generated randomization sequence with allocation concealed using sealed opaque envelopes.

Before induction of general anesthesia, the assigned regional block will be performed under mild sedation and real-time ultrasound guidance by an experienced anesthesiologist. Participants assigned to the ITPB group will receive bilateral intertransverse process block at the T6-7 and T9-10 levels. Participants assigned to the comparator group will receive bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block.

Both groups will receive 0.3% ropivacaine at four injection sites, with 15 mL administered at each site, for a total volume of 60 mL and a total dose of 180 mg. In participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

Sensory block will be assessed using cold and pinprick testing at 5, 15, and 30 minutes after block placement. Participants, anesthesia and postoperative care providers, postoperative outcome assessors, and the statistical analyst will remain masked to treatment allocation. Because of the nature of the procedure, the anesthesiologist performing the assigned regional block cannot be masked and will not participate in subsequent postoperative management or outcome assessment.

All participants will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. Postoperative outcomes will be assessed at 2, 4, 6, 12, 24, 48, and 72 hours after surgery and at discharge as applicable.

Blood samples will be collected at 35 minutes, 60 minutes, 90 minutes, 2 hours, 6 hours, and 25 hours after completion of the regional block.

Tipo di studio

Interventistico

Iscrizione (Stimato)

64

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Bon-Nyeo Koo, Professor
  • Numero di telefono: +82-10-6208-5797
  • Email: KOOBN@yuhs.ac

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

19 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Adults aged 19 years or older. American Society of Anesthesiologists physical status I-III. Scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia.

Able to understand and use patient-controlled analgesia (PCA). Able to understand the purpose and procedures of the study and voluntarily provide written informed consent.

Exclusion Criteria:

History of allergy to local anesthetics or study medications. Coagulopathy, defined as INR > 1.5 or platelet count < 70,000/μL, or current anticoagulant use.

Infection at the regional block site. History of chronic pain or chronic opioid use for 3 months or longer. History of drug or alcohol abuse or dependence. Severe cardiopulmonary dysfunction or neurological disease. Cognitive impairment or psychiatric disease preventing cooperation with pain assessment, including the Numerical Rating Scale (NRS).

Body mass index (BMI) < 18 or > 35 kg/m². Pregnancy or breastfeeding. Scar at the block site that interferes with ultrasound visualization or local anesthetic spread.

History of abdominal surgery.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: ITPB Group

Participants will receive ultrasound-guided bilateral intertransverse process block at the T6-7 and T9-10 levels before induction of general anesthesia.

Before induction of general anesthesia and under mild sedation, bilateral intertransverse process block will be performed under real-time ultrasound guidance at the T6-7 and T9-10 levels. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

Altri nomi:
  • ITPB
  • Intertransverse Process Block
Comparatore attivo: TAP + Rectus Sheath Block Group

Participants will receive ultrasound-guided bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block before induction of general anesthesia.

Before induction of general anesthesia and under mild sedation, bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block will be performed under real-time ultrasound guidance. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.

Altri nomi:
  • TAP Blocca
  • Blocco del piano trasverso dell'addome
  • Rectus Sheath Block

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cumulative Postoperative Opioid Consumption at 24 Hours
Lasso di tempo: From the end of surgery through 24 hours postoperatively

Cumulative opioid consumption during the first 24 hours after surgery will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents and summing the converted doses.

From the end of surgery through 24 hours postoperatively

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cumulative Postoperative Opioid Consumption at Additional Time Points
Lasso di tempo: At 2, 4, 6, 12, 48, and 72 hours postoperatively.

Cumulative postoperative opioid consumption at each specified time point will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents.

At 2, 4, 6, 12, 48, and 72 hours postoperatively.
Incisional Pain Intensity
Lasso di tempo: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

Incisional or somatic pain intensity will be assessed separately using the Numeric Rating Scale (NRS).

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Visceral Pain Intensity
Lasso di tempo: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

Deep or visceral abdominal pain intensity will be assessed separately using the Numeric Rating Scale (NRS). Participants will be instructed preoperatively to distinguish deep or generalized abdominal pain from pain at the incision site.

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Shoulder Pain Incidence and Intensity Assessed Using the Numeric Rating Scale (NRS)
Lasso di tempo: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

The presence of postoperative shoulder pain associated with diaphragmatic irritation will be recorded, and its intensity will be assessed using the Numeric Rating Scale (NRS).

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Extent and Distribution of Sensory Block
Lasso di tempo: At 5, 15, and 30 minutes after completion of the regional block.

Sensory block will be assessed using cold and pinprick testing. The highest and lowest blocked dermatomes, the total number of blocked dermatomes, anterior and posterior spread, and the presence or absence of posterior/paravertebral sensory block will be recorded.

At 5, 15, and 30 minutes after completion of the regional block.
Pain Intensity at Rest and During Coughing or Movement
Lasso di tempo: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

Pain intensity at rest and during coughing or movement will be assessed using the Numeric Rating Scale (NRS).

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Time to First Rescue Analgesic Request
Lasso di tempo: Up to 72 hours after surgery.

Time to the first request for rescue analgesia will be recorded.

Up to 72 hours after surgery.
Frequency of Rescue Analgesic Administration
Lasso di tempo: During the first 48 hours postoperatively.

The number of rescue analgesic administrations during the first 48 postoperative hours will be recorded.

During the first 48 hours postoperatively.
Quality of Recovery-15 (QoR-15) Score
Lasso di tempo: On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).

Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire on postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).

On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).
Time to First Flatus
Lasso di tempo: From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).

The time to first postoperative flatus will be recorded.

From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).
Time to First Ambulation
Lasso di tempo: From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).

The time to first postoperative ambulation will be recorded.

From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).
Postoperative Length of Hospital Stay
Lasso di tempo: From surgery through hospital discharge, an expected average of approximately 8 days.

Postoperative length of hospital stay will be recorded as the number of calendar days from the date of surgery to hospital discharge. The date of surgery will be defined as postoperative day (POD) 0.

From surgery through hospital discharge, an expected average of approximately 8 days.
Opioid-Related Adverse Events
Lasso di tempo: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.

The incidence of opioid-related adverse events, including nausea, vomiting, excessive sedation, respiratory depression, pruritus, urinary retention, and reduced gastrointestinal motility, will be assessed.

At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
Block-Related Complications
Lasso di tempo: From regional block placement through 72 hours postoperatively.

The incidence of block-related complications, including pneumothorax, pleural puncture, hematoma, infection, local anesthetic systemic toxicity, nerve injury, lower-limb weakness, unintended neuraxial block, and intra-abdominal organ injury, will be assessed.

From regional block placement through 72 hours postoperatively.
Comprehensive Complication Index (CCI)
Lasso di tempo: At hospital discharge, an expected average of approximately 8 days after surgery.

Postoperative complications will be assessed using the Comprehensive Complication Index (CCI) through hospital discharge.

At hospital discharge, an expected average of approximately 8 days after surgery.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

19 ottobre 2026

Completamento primario (Stimato)

22 aprile 2028

Completamento dello studio (Stimato)

25 settembre 2028

Date di iscrizione allo studio

Primo inviato

5 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 4-2026-1244

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .